Regorafenib-Triggered Hemophagocytic Lymphohistiocytosis: A Report of Two Cases.

Hemophagocytic lymphohistiocytosis (HLH) is a rare, potentially fatal condition, characterized by overactivation of the immune system. It can manifest as primary or secondary when triggered by infections, neoplasms, or medications. We report here two cases of regorafenib-induced HLH, one of which was life-threatening.

Survival and relative dose intensity of 5-fluorouracil, oxaliplatin and irinotecan in real-life treatment of metastatic colorectal cancer.

Introduction: Combinations of 5-fluorouracil/leucovorin (5-FU/LV) with oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) are part of standard treatments for metastatic colorectal cancer (mCRC). For these molecules, the impact of a low relative dose intensity (RDI) on survival is not sufficiently known in real-life.

Material And Methods: Data were collected retrospectively from patients treated in our center for an unresectable mCRC with FOLFOX or FOLFIRI as a first-line treatment.

Characterization of a viral phosphoprotein binding site on the surface of the respiratory syncytial nucleoprotein.

The human respiratory syncytial virus (HRSV) genome is composed of a negative-sense single-stranded RNA that is tightly associated with the nucleoprotein (N). This ribonucleoprotein (RNP) complex is the template for replication and transcription by the viral RNA-dependent RNA polymerase. RNP recognition by the viral polymerase involves a specific interaction between the C-terminal domain of the phosphoprotein (P) (P(CTD)) and N.